Baxter and ScinoPharm Partner to Develop Generic Oncology Injectables

Baxter International and ScinoPharm Taiwan have teamed up in a strategic partnership to develop, manufacture, and commercialize generic oncology injectables, according to a press release.

The partnership will include 5 injectable drugs used in a variety of cancer treatments, including lung cancer, multiple myeloma, and breast cancer, and allows Baxter the option to partner with ScinoPharm on up to 15 additional injectable molecules. Plans also call for the development of treatments for adverse effects that are associated with chemotherapy, such as nausea and vomiting.

Both companies will partner on the product development and manufacturing aspects of the injectables, and Baxter will hold commercialization rights.

Baxter’s multifaceted portfolio includes various generic injectable medications, including difficult-to-manufacture oncology drugs as well as standard-dose, ready-to-use premixed injectable products such as anti-infectives, analgesics, and critical care medicines. ScinoPharm is known for manufacturing APIs for the pharmaceutical industry, and will provide APIs for the initial 5 generic injectables slated for development.

“Combining Baxter’s differentiated manufacturing expertise and global commercialization capabilities with ScinoPharm’s recognized API experience enables Baxter to increase patient access to difficult-to-manufacture, high-quality oncolytic medicines,” Robert Felicelli, president, Pharmaceuticals, Baxter, said in a press release.

The 5 generic injectables are expected for launch beginning in 2020.